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Abstract
Background: Patients with peripheral arterial disease (PAD) under-
going percutaneous coronary intervention (PCI) are at elevated risk of 
ischemic and bleeding events. However, the optimal duration of dual 
antiplatelet therapy (DAPT) after PCI in patients with PAD remains 
unclear.
Methods: A systematic literature search was performed through 
June 2017 using PubMed, EMBASE and Cochrane databases with 
the following key terms: “dual antiplatelet therapy”, “P2Y12 inhibi-
tor”, “myocardial infarction”, “percutaneous coronary intervention”, 
“stent”, “peripheral arterial disease”, and “ankle-brachial index”. The 
analysis was restricted to randomized trials published in English in 
patients with PAD receiving extended DAPT (> 12-month) after PCI. 
Overall analysis was performed using Review Manager 5.3 with the 
Mantel-Haenszel method.
Results: Two randomized controlled trials involving 895 patients 
were included in this review. Compared to the placebo group, there 
was no statistical significance in the occurrence of major adverse 
cardiovascular and cerebrovascular events (MACCE) in patients re-
ceiving extended DAPT (odds ratio (OR) 0.76, 95% confidence in-
terval (CI) 0.37 - 1.57; P = 0.46). The results were associated with 
substantial heterogeneity (I2 = 71%, P = 0.07). Extended DAPT was 
not significantly associated with increased moderate/severe bleeding 
events (OR 1.63, 95% CI 0.84 - 3.18; P = 0.15; I2 = 0%, P = 0.59). 
The extended DAPT was associated with 82% relative risk reduction 
in the events of definite/probably stent thrombosis.
Conclusions: Among patients with PAD, extended DAPT after PCI 
resulted in a non-significant difference in ischemic and bleeding 
events compared to placebo, respectively. The routine use of extended 
DAPT in this cohort should be carefully evaluated.
Keywords: DAPT, PCI, PAD
Introduction
Peripheral arterial disease (PAD) is associated with more 
extensive and calcified coronary atherosclerosis, constric-
tive arterial remodeling, and greater disease progression in 
patients with coronary artery disease, thus contributing to ad-
verse cardiovascular outcomes [1]. It is estimated that PAD 
affects approximately 8.5 million people in the United States 
[2]. It is reported that two out of three patients with PAD had 
coexistent coronary arterial disease (CAD) and one in five 
patients with CAD had coexistent PAD [3, 4]. Patients with 
PAD undergoing percutaneous coronary intervention (PCI) 
are at elevated risk of adverse clinical events. The data from 
the Dutch Stent Thrombosis Registry found that PAD was an 
independent risk factor associated with 5.62-fold increased 
odds of late (> 30 days) stent thrombosis [5]. Patients with 
PAD were also reported to have a 2-fold increase risk of 
death and a trend toward higher major bleeding complica-
tions after PCI [4, 6]. Dual antiplatelet therapy (DAPT) with 
aspirin and a P2Y12 inhibitor after PCI is generally recom-
mended to reduce the risk of stent thrombosis and ischemic 
events, which unfortunately may be offset by the increased 
risk of bleeding [7]. The optimal duration of DAPT has been 
debated in the past few decades and decisions regarding du-
ration of DAPT require a comprehensive assessment of the 
benefits of treatment, bleeding risk, and patient preference. 
In the PEGASUS-TIMI 54 (Prevention of Cardiovascular 
Events in Patients With Prior Heart Attack Using Ticagrelor 
Compared to Placebo on a Background of Aspirin-Thrombol-
ysis In Myocardial Infarction 54) trial, DAPT with a median 
treatment duration of 33 months achieved approximately 
40% reduction in cardiovascular death, myocardial infarction 
(MI), or stroke in patients with PAD, compared to patients 
without PAD [6]. A non-significant increase of Thromboly-
sis in Myocardial Infarction (TIMI) major or minor bleed-
ing was observed in patients with PAD treated with DAPT 
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in the PEGASUS-TIMI 54 trial. Similar findings have been 
reported in the CHARISMA (Clopidogrel for High Athero-
thrombotic Risk and Ischemic Stabilization, Management, 
and Avoidance) trial with 40% reduction in MI in patients 
received DAPT for 28 months [8]. That said, patients with 
PAD in CHARISMA trial experienced almost 70% increase 
of minor bleeding compared to aspirin monotherapy (20.4% 
vs. 34.4%). Considering the elevated risk of ischemic and 
bleeding events in patients with PAD undergoing PCI, it is 
uncertain about whether DAPT should be extended beyond 
12 months based on the benefit-risk profile. We conducted a 
meta-analysis on this topic to better understand the benefits 
and risks of DAPT beyond 12-month for secondary preven-
tion in patients with PAD undergoing PCI.
Methods
The studies included in the meta-analysis to evaluate the dura-
tion of DAPT in patients with PAD undergoing PCI were iden-
tified by conducting a systematic review of literature indexed 
in database PubMed, EMBASE and Cochrane databases. 
Key words used to conduct the search were “dual antiplatelet 
therapy”, “P2Y12 inhibitor”, “myocardial infarction”, “percu-
taneous coronary intervention”, “stent”, “peripheral arterial 
disease”, and “ankle-brachial index”. The literature search was 
performed through June 2017. In addition, published confer-
ence abstracts, review articles, and editorials were reviewed 
for further information.
The meta-analysis included original research that met the 
following inclusion criteria: 1) randomized controlled study as 
design; 2) published in English; 3) conducted in patients with 
PAD undergoing coronary stenting with either drug-eluting st-
ents (DES) or bare metal stents; and 4) compared the efficacy 
of extended DAPT (> 12-month) vs. non-extended DAPT (≤ 
12-month). The exclusion criteria were as follows: 1) studies 
whose analysis did not include patients with PAD; 2) studies 
that did not have controls.
The primary endpoint for this analysis was the incidence 
of MACCE, defined as a composite of all-cause death, MI, and 
stroke. Incidence of GUSTO (the Global Use of Strategies to 
Open Occluded Coronary Arteries) moderate/severe bleeding 
was used for the safety endpoint. Events of definite or probable 
stent thrombosis, MI, cardiac death, and all-cause death were 
also evaluated.
This meta-analysis followed the guidelines of the PRIS-
MA Statement 2009 [9]. The two authors independently as-
sessed the eligibility of trials and extracted the data. Disagree-
ments were resolved by consensus. The Cochrane Risk of Bias 
Tool was used to assess bias risk. All statistical analyses were 
performed by Review Manager 5.3 (Nordic Cochrane Centre, 
Cochrane Collaboration) using the Mantel-Haenszel method 
with either random effects or fixed effects models based on 
the level of heterogeneity. Odds ratio (OR) of efficacy and 
safety end points were calculated from the included studies 
in patients with PAD undergoing PCI receiving extended vs. 
non-extended DAPT. We tested heterogeneity of the included 
studies with Cochran Q statistics and the extent of inconsist-
ency between results with I2 statistics with significance set at a 
P value of 0.10. Data are presented as OR with 95% confidence 
intervals (CI), with two-tailed P values and statistical signifi-
cance set at P value < 0.05.
Results
Overall, 185 citations met the search criteria to be assessed. 
After deleting 59 duplications, 126 citations were reviewed 
in detail for eligibility. Most citations were excluded because 
they were review articles, abstracts, editorials, non-randomized 
registry studies, or not relevant to our topic (Fig. 1). Particu-
larly, the CHARISMA trial was excluded because it compared 
DAPT vs. aspirin monotherapy in patients with PAD [8]. The 
PEGASUS-TIMI 54 trial was excluded because it included pa-
tients with MI that occurred 1 - 3 years prior to enrollment [6]. 
Furthermore, patients in PEGASUS-TIMI 54 trial were also 
not required to have a history of PCI with stenting.
After exclusion, two randomized controlled trials involv-
ing 895 patients were included in this analysis. The main de-
scription of both studies and the participants’ characteristics 
Figure 1. Summary of the study selection and exclusion process.
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are listed in Table 1. The PRODIGY (Prolonging Dual Anti-
platelet Treatment After Grading Stent-Induced Intimal Hy-
perplasia Study) trial was a randomized, multicenter, open-
label study, and the subanalysis of PRODIGY trial assessed 
the efficacy and safety of prolonged (24-month) vs. short (≤ 
6-month) DAPT (clopidogrel plus aspirin) in 246 and 1,724 
patients with and without PAD undergoing PCI, respectively 
[10]. The DAPT trial was a randomized, double-blind, place-
bo-controlled trial, and the subanalysis of the DAPT trial eval-
uated the efficacy of extended DAPT (clopidogrel or prasugrel 
plus aspirin; 30-month vs. 12-month) in reducing ischemic 
events and the safety profile of extended DAPT in 10,999 
non-PAD vs. 649 PAD patients [11]. Of note, approximately 
half participants in both the PRODIGY and the DAPT trial 
received everolimus-eluting stent or zotarolimus-eluting stent, 
which are considered as new-generation DES with less risk of 
stent thrombosis.
The incidence of MACCE was 12.8% (56/437 patients) 
when receiving extended DAPT vs. 15.5% (71/458 patients) 
in patients received non-extended DAPT, representing a non-
significant relative risk reduction (OR = 0.76; 95% CI 0.37 - 
1.57; P = 0.46) (Fig. 2). The Chi-square test for heterogeneity 
was significant at a level of less than 0.10 (P = 0.07). The I2 
value was 70%. These quantitative results suggest there was 
study variability.
The occurrence of GUSTO moderate/server bleeding was 
5.0% (22/437 patients) when receiving extended DAPT vs. 
3.1% (14/458 patients) when receiving non-extended DAPT 
(OR = 1.67; 95% CI 0.84 - 3.32; P = 0.14) (Fig. 3). Extended 
DAPT was not significantly associated with increased GUSTO 
moderate/severe bleeding events, without heterogeneity be-
tween studies.
The extended DAPT was associated with 82% relative 
risk reduction in the events of definite/probably stent throm-
bosis, compare to the non-extended DAPT (OR = 0.18; 95% 
CI 0.05 - 0.68; P = 0.01) (Fig. 4). The risk reduction represent-
ed an absolute risk difference of 2.60% or a number needed to 
treat of 38 to prevent one stent thrombosis over an extended 
duration of DAPT. However, this significant reduction in stent 
thrombosis was not accompanied by any significant reduction 
in MI, cardiac death, or all-cause death. (Fig. 5-7) Though 
there was little heterogeneity in the analysis of stent thrombo-
Table 1.  Summary of the DAPT Trial and PRODIGY Trial
The PRODIGY trial The DAPT trial
No of patients 1970 11,648
No of patients with PAD 246 649
Randomization groups Aspirin 75 - 160 mg/d + clopidogrel 
75 mg/d vs. aspirin + placebo
Aspirin 75 - 162 mg/d + clopidogrel 75 mg/d 
or prasugrel 10/5 mg/d vs. aspirin + placebo
Follow-up ≤ 6-month vs. 24-month 12-month vs. 30-month
Age among patients with PAD (SD) 74.5 (8.94) 66.2 (9.57)
Male among patients with PAD 76.83% 70.42%
Diabetes mellitus among patients with PAD 33.74% 44.29%
Hypertension among patients with PAD 87.40% 87.98%
Smoking among patients with PAD 15.45% 28.55%
Congestive heart failure among patients with PAD 6.50% 14.73%
Prior PCI among patients with PAD 23.98% 40.87%
Prior CABG among patients with PAD 17.89% 25.15%
Prior MI among patients with PAD 40.65% 30.77%
Indication for PCI
  STEMI among patients with PAD 20.32% 4.62%
  NSTE-ACS among patients with PAD 52.44% 26.81%
  Stable angina among patients with PAD 27.23% 44.53%
CABG: coronary artery bypass grafting; MI: myocardial infarction; PAD: peripheral artery disease; SD: standard deviation.
Figure 2. MACCE associated with a short versus extended DAPT use in patients with PAD after PCI.
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sis and MI, the analysis of cardiac death and all-cause death 
were associated with substantial heterogeneity, indicating 
study variability.
The risk of bias in included studies was low or unclear 
in most areas in both studies (Fig. 8). The performance bias 
and attrition bias were the main potential sources of bias in 
the PRODIGY trial. The open-label design of the PRODIGY 
trial may have introduced a potential for performance bias, and 
more patients in the short-term arm were reported to discontin-
ue clopidogrel after the first month (12% vs. 0.2%), which was 
allowed in patients who were randomized to a BMS. However, 
the discontinuation rate was not reported in the PAD popula-
tion, so it is unclear about attrition bias in the subgroup analy-
sis of the PRODIGY trial.
Figure 3. GUSTO moderate/severe bleeding events associated with a short versus extended DAPT use in patients with PAD 
after PCI.
Figure 4. Definite or probable stent thrombosis events associated with a short versus extended DAPT use in patients with PAD 
after PCI.
Figure 5. MI events associated with a short versus extended DAPT use in patients with PAD after PCI.
Figure 6. Cardiac death events associated with a short versus extended DAPT use in patients with PAD after PCI.
Figure 7. All-cause death events associated with a short versus extended DAPT use in patients with PAD after PCI.
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Discussion
Our meta-analysis of two randomized controlled trials involv-
ing 895 patients with PAD undergoing PCI found a non-sta-
tistically significant reduction of MACCE in patients receiv-
ing extended DAPT. The extended duration of DAPT was not 
significantly associated with increased GUSTO moderate/se-
vere bleeding events either. A substantial reduction of definite/
probably stent thrombosis was observed in the extended DAPT 
group. Unfortunately, the reduction of stent thrombosis alone 
was not able to reduce the occurrence of MI, cardiac death, and 
all-cause death significantly. The analysis of MACCE, cardiac 
death, and all-cause death were associated with substantial het-
erogeneity.
The subanalysis of the DAPT trial and PRODIGY trial 
found that PAD was associated with increased risk of is-
chemic and bleeding events after PCI, which were consist-
ent with the previous findings in the CHARISMA trial and 
PEGAUSIS-TIMI 54 trial. In general, the PAD patients 
were usually older and more likely to have hypertension, 
MI, multiple stents, and diabetes mellitus. In the DAPT trial 
and PRODIGY trial, patients with PAD were associated with 
higher rates of stent thrombosis, MI, MACCE compared with 
patients without PAD, indicating that PAD is a risk factor of 
adverse health outcomes (Table 2). The incidence of GUSTO 
moderate/severe bleeding was significantly higher in patients 
with PAD compared with patients without PAD in the DAPT 
trial, though the rate of bleeding-related death was similar 
[11]. Interestingly, the increased rate of GUSTO moderate/
severe bleeding was not observed in the PRODIGY trial, 
which could be explained by the small sample size and inad-
equate power [10]. Due to the evaluated risk of ischemic and 
bleeding events in patients with PAD, it will be necessary to 
investigate if the duration of DAPT should be tailored based 
on the status of PAD.
Current guidelines recommend at least 12-month treat-
ment of DAPT in patients following MI, however, the duration 
of DAPT has been debated since the beginning of DAPT [7]. 
The DAPT trial found reduced ischemic event and increased 
bleeding, thus suggesting the extended duration could be used 
in patients at high ischemic patients with low bleeding risk 
[12]. Subsequently, subgroup studies have been conducted to 
define adequate patients for use of extended DAPT therapy. 
However, to the best of our knowledge, very few trials have 
been conducted in patients with PAD, which were also lim-
ited by small sample size. By using meta-analysis, we intended 
to combine the limited results together to advance our under-
standing the role of extended DAPT in patients with PAD un-
dergoing PCI.
This meta-analysis did not detect a significant reduction in 
MACCE, cardiac death and all-cause death in extended DAPT 
group in patients with PAD after PCI. It seems that the elevated 
all-cause death rate in the extended DAPT group is not linked 
to the increased bleeding rate [13]. A post-hoc analysis of the 
DAPT trial identified a significant difference of cancer related 
deaths in both groups (0.6% vs. 0.3%, P = 0.02) [13]. After 
adjusting the cancer incidence, a sensitive analysis revealed 
a non-significant death rate in both groups, suggesting that 
the non-significant reduction of MACCE and all-cause death 
may be explained by the imbalanced baseline characteristics 
in both groups [13]. In addition, the duration of non-extended 
DAPT in the PRODIGY trial was only 6 month [14]. For 50% 
of the patients in the PRODIGY trial who received bare mental 
stent and first-generation DES, it is recommended to receive 
DAPT at least 12-month. The new-generation stents have been 
tested in the non-ACS patients showing non-inferior effective-
ness in 6-month vs. 12-month [15]. Nevertheless, the duration 
Table 2.  Effect of PAD on Clinical Outcomes in the DAPT Trial and PRODIGY Trial
DAPT trial PRODIGY trial
% Patients with 
PAD (n = 649)
% Patients without 
PAD (n = 10,999) P value
% Patients with 
PAD (n = 246)
% Patients without 
PAD (n = 1,724) P value
MACCE 11.65 (73) 4.62 (494) < 0.001 21.9 (54) 8.4 (144) < 0.001
MI 5.88 (36) 2.90 (308) < 0.001 7.5 (18) 3.6 (62) 0.006
Definite/probable ST 1.47 (9) 0.83 (88) 0.094 3.0 (7) 1.2 (21) 0.04
GUSTO moderate/severe bleeding 4.86 (30) 1.74 (185) < 0.001 2.6 (6) 2.7 (45) 0.95
ST: stent thrombosis; MACCE: major adverse cardiovascular and cerebrovascular event; MI: myocardial infarction.
Figure 8. Risk of bias graph for the studies included in this systematic 
review. Green +: yes (low risk of bias); yellow ?: unclear; red -: no (high 
risk of bias).
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of DAPT in ACS patients with new-generation stent has not 
been fully examined. Therefore, the increased incidence of 
MACCE and cardiac-death in the non-extended DAPT group 
could be attributed to the increased stent thrombosis events be-
cause of insufficient protection from the short duration DAPT 
(6-month).
The GUSTO moderate and severe bleeding risk was not 
significantly increased in the extended DAPT group in our 
meta-analysis. This result is consistent with a recent meta-
analysis of 21,534 participants from three trials of post-MI pa-
tients received DAPT beyond 12-month [16]. The odds ratio of 
major bleeding and fatal bleeding were 1.53 (0.92, 2.52) and 
1.12 (0.66, 1.90) with both P values higher than 0.05. (P = 0.10 
and P = 0.69). In the PEGASUS-TIMI 54 trial subanalysis, 
neither TIMI major nor minor bleeding was associated with 
extended DAPT in patients with PAD [6]. In the CHARISMA 
trial subanalysis, there was no significant difference in the rate 
of severe, fatal, or moderate bleeding, though minor bleeding 
was reported to increase almost 2-fold in the extended DAPT 
group in the CHARISMA trial [8].
There were high levels of heterogeneity in the analyses of 
MACCE, cardiac death and all-cause death, which could be 
explained by the differences between the two trials in treat-
ment lengths and baseline characteristics of study participants, 
though little heterogeneity was observed in stent thrombosis, 
MI, and GUSTO moderate/severe bleeding. Participants in 
the PRODIGY trial were more likely to have older age and 
previous MI. It was reported that more than 50% participants 
had acute MI at presentation in the PRODIGY trial, and less 
than 25% patients had stable CAD compared to 45% patients 
with stable CAD in the DAPT trial. Hence, patients in the 
PRODIGY trial presented more acute conditions, and thereby 
might benefit more from the extended DAPT. Also as afore-
mentioned, there was an imbalance of cancer in the baseline 
characteristics between groups in the DAPT trial, potential-
ly increased the all-cause death rate in the treatment group. 
Furthermore, the duration of non-extended DAPT group was 
6-month in PRODIGY trial vs. 12-month in the DAPT tri-
al. Patients in the non-extended DAPT group (6-month) of 
PRODIGY trial was associated with significant increase in 
MACCE and a non-significant change of definite or probable 
stent thrombosis, indicating short duration DAPT (6-month) 
may not be able to provide enough protection in ACS patients 
with a comorbidity of PAD receiving new-generation DES, 
causing overestimation of the benefits of extended DAPT in 
MACCE in our results.
There are certain limitations in our meta-analysis. Al-
though we have conducted a comprehensive search by two 
persons independently, only two randomized clinical trials 
were eligible and included in our study. Theoretically, two tri-
als are the minimal requirement to conduct a meta-analysis, 
and more studies provide a more precise estimation of the 
true effect than each trial alone. To achieve valid statistical 
inferences, the random-effects method was used to combine 
treatment effects when the presence of between-trial hetero-
geneity is suspected. The combination of only a few studies 
is not uncommon, especially in cases of rare diseases [17]. In 
an analysis of 22,453 meta-analyses from the Cochrane Data-
base of Systematic Reviews, more than one third of the meta-
analyses included the minimum requirement of two studies 
only, and close to 75% meta-analyses contained five or fewer 
studies [18]. Nevertheless, the meta-analysis of only two stud-
ies in the presence of heterogeneity may be considered an un-
solved problem and beyond the scope of this study [19]. We 
acknowledge that the low number of studies makes it difficult 
to estimate the between-studies variance in random-effects 
analysis, and some of our results should be interpreted with 
caution. Moreover, procedural factors of the initial PCI play 
a major role in determining the risk of ischemic events. For 
example, it must be noted that substantial patients received 
new-generation DES in both trials, however, the percentage 
of participants with new-generation DES was not reported in 
their subanalysis. New-generation of DES has been reported 
with 50% less risk of stent thrombosis compared with the first-
generation stent. Indeed, the recent guidelines suggested that 
6-month DAPT is reasonable after new-generation DES im-
plantation in patients with stable CAD. Unfortunately, because 
of the nature of our data, we had no access to patients’ specific 
data thus were not able to identify if the percentage of new-
generation DES implantation will affect our results.
Conclusions
Patients with PAD undergoing PCI are at elevated risk of car-
diovascular morbidity and mortality due to increased ischemic 
and bleeding events. Among patients with PAD, extended 
DAPT after PCI resulted in a non-significant difference in 
MACCE, cardiac death, all-cause death and bleeding events 
and a significant reduction in stent thrombosis and MI com-
pared to placebo. The review was limited by the small number 
of published trials and high level of heterogeneity in MACCE, 
cardiac death and all-cause death. Our results showed that the 
routine use of extended DAPT in patients with PAD undergo-
ing PCI provided a neutral effect on cardiac outcomes, and 
further studies with adequate power are needed to substantiate 
the role of extended DAPT in this cohort, especially with new-
generation DES.
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